News
2 minute read

MBHB Partner Kevin Noonan Quoted in BioPharma-Reporter.com Article Entitled, "AbbVie’s Humira IP strategy having ‘chilling effect on competition,’ UK judge"

Kevin E. Noonan, Ph.D.January 18, 2017

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a January 18, 2017 online edition of BioPharma-Reporter.com in an article entitled, “AbbVie’s Humira IP strategy having ‘chilling effect on competition,’ UK judge.” A UK judge says a vexatious litigation strategy is staving off Humira biosimilars, but AbbVie is “playing by the rules and incurring the costs of doing so,” according to an IP lawyer. View the article